Free Trial

Novo Nordisk: More Good News

HEALTHCARE
  • Novo Nordisk (NOVOB: A1/AA-): Good news from UK Study
  • More good news for Novo Nordisk (and Eli Lilly)

    The Times reports “The largest study ever into semaglutide, also known as Ozempic or Wegovy, found the drug cuts heart disease deaths by about 20 per cent even if people don’t lose weight. Millions of middle-aged Britons should be routinely prescribed weight-loss injections to cut their risk of heart attacks and strokes by a fifth, according to a trial set to revolutionise medical practice.”
  • {https://www.thetimes.co.uk/article/uk-weight-loss-jabs-prescription-drugs-ozempic-7dbsvkblg}

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.